<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01613092</url>
  </required_header>
  <id_info>
    <org_study_id>PADIT Cluster Crossover Pilot</org_study_id>
    <nct_id>NCT01613092</nct_id>
  </id_info>
  <brief_title>Prevention of Arrhythmia Device Infection Trial (PADIT)</brief_title>
  <official_title>Prevention of Arrhythmia Device Infection Trial (PADIT) Cluster Crossover Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the pilot study is to compare whether a centre-wide policy of incremental
      antibiotic therapy will reduce pacemaker infection compared to a policy of conventional
      antibiotic prophylaxis in high-risk patients undergoing arrhythmia device procedures. This
      pilot study will provide feasibility information for a larger cluster randomized crossover
      design (CRCD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center, cluster crossover, unblinded, pilot study. Centers will be randomized to
      conventional vs. incremental antibiotic therapy for 2 months or until eligible 20 patients
      are treated, whichever comes first. At 2 months, centers will have a crossover period of 4
      weeks where the alternate strategy is implemented, followed by the final 2-month/20 patient
      enrolment period. During each treatment period the randomized antibiotic strategy will be
      used on all center patients undergoing a device implant procedure. Prior to the planned
      surgery or at the first follow up visit, patients who meet the study eligibility criteria
      will be approached to obtain consent for data collection purposes. Follow up will be
      according to usual clinical care at the center.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospitalization attributed to device infection</measure>
    <time_frame>within one year of device procedure</time_frame>
    <description>Hospitalization attributed to device infection</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">241</enrollment>
  <condition>Arrhythmia</condition>
  <arm_group>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative Antibiotics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aggressive (Incremental)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preoperative antibiotics, antibiotic wash and post operative antibiotics</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Incremental</intervention_name>
    <description>Cefazolin and Vancomycin pre-op, bacitracin wash and postoperative cefalexin or clindamycin</description>
    <arm_group_label>Aggressive (Incremental)</arm_group_label>
    <other_name>Cefazolin , Vancomycin, bacitracin, cefalexin or clindamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin</intervention_name>
    <description>Preoperative antibiotic</description>
    <arm_group_label>Conventional</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 years

          -  received one of the following procedures:

               1. a second or subsequent procedure on the arrhythmia device pocket: i. ICD,
                  pacemaker, CRT-P, CRT-D generator and/or lead replacement. ii. pocket or lead
                  revision iii. system upgrade (insertion or attempted insertion of leads)

               2. new cardiac resynchronization therapy device implant (pacemaker or ICD)

        Exclusion Criteria:

          -  life expectancy &lt; 12 months in the opinion of the local investigator.

          -  allergy or unable to tolerate cefazolin or clindamycin or vancomycin.

          -  allergy or unable to tolerate intracavitary bacitracin identified per-operatively.

          -  pre-operative identification that the patient has infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Andrew Krahn, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hamilton General Hospital, McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2012</study_first_submitted>
  <study_first_submitted_qc>June 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2012</study_first_posted>
  <last_update_submitted>October 9, 2014</last_update_submitted>
  <last_update_submitted_qc>October 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arrhythmia</keyword>
  <keyword>Device Procedure</keyword>
  <keyword>High risk patients</keyword>
  <keyword>Antibiotics</keyword>
  <keyword>Infection</keyword>
  <keyword>Cluster</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Cephalexin</mesh_term>
    <mesh_term>Bacitracin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

